Ethris secures €30M EIB loan to advance mRNA antiviral ETH47
Ethris GmbH has signed a €30 million financing agreement with the European Investment Bank, backed by the European Commission's Health Emergency Preparedness and Response Authority (DG HERA), to advance clinical development of its respiratory mRNA portfolio. The deal, formalised at the company's Munich headquarters, will primarily fund ETH47, its lead mRNA candidate, through Phase 2b trials in patients with asthma and chronic obstructive pulmonary disease.
ETH47 works by encoding interferon lambda (IFNλ), a cytokine that stimulates localised innate immune defences in the respiratory mucosa. Because it targets the host immune pathway rather than a specific viral protein, the company positions it as broadly active against multiple respiratory virus families, including the seasonal and novel pathogens that drive exacerbations in asthma and COPD patients. The candidate is currently in a Phase 2a trial evaluating antiviral activity in asthma, administered via inhalation or nasal spray using Ethris' proprietary lipid nanoparticle delivery system.
The funding also covers two earlier-stage programmes: ETH52 and ETH53, which are focused on mucosal influenza vaccines and broader pandemic preparedness.
Clinical and regulatory context
Carsten Rudolph, chief executive and co-founder of Ethris, said the financing would allow the company to provide "further clinical proof of concept of our novel approach targeting viral threats at the point of entry." The move from Phase 2a to Phase 2b is a meaningful step: the company will need to demonstrate not just antiviral activity but a clinically meaningful reduction in exacerbation rates, with adequate power and trial design to satisfy regulators in both the EU and, prospectively, the US. EMA guidance on inhalation-route biologics has become more detailed in recent years, and the nasal-spray administration route will require its own device characterisation package alongside the biological data.
The HERA Invest mechanism, through which EIB is channelling the funds, is a €130 million top-up to the InvestEU programme financed by EU4Health. It is restricted to small and mid-sized companies developing clinical-stage medical countermeasures against pandemic pathogens, antimicrobial resistance, chemical and biological threats, and vector-borne disease. Ethris' dual positioning as a chronic disease and pandemic preparedness play is notable: it broadens the addressable market while aligning the programme with European sovereign health-security priorities.
Market landscape
The broad-spectrum antiviral space has attracted renewed attention since the Covid-19 pandemic exposed gaps in rapid-response therapeutic infrastructure. Several approaches are in development across academic and commercial settings, including other interferon-based strategies and host-directed small molecules, though few have reached late-stage clinical evaluation via the inhalation or nasal route. Ethris' SNIM mRNA platform, which the company says improves mRNA stability and reduces immunogenicity, is a differentiating feature: instability and unintended immune activation have historically limited the direct pulmonary delivery of nucleic acid therapeutics.
The EIB's participation, rather than a private lead investor, reflects the strategic-asset framing of pandemic preparedness in European policy rather than pure commercial appetite. Private biotech investors will watch the Phase 2b readout timeline closely before making their own valuation judgements on the platform. Ethris has not disclosed a post-money valuation or indicated whether it intends to seek a partnership or IPO as the next major corporate milestone.